Knee Gel Injection Cost: Every Product, at Medicare's Own Price

Medicare's Allowed Amount for a Full Course, by Product

Part B pays for these gels off a quarterly published payment limit (average sales price plus 6%). These are the limits in effect October 1 through December 31, 2026, multiplied by the labeled dose, times the number of injections in the labeled series, plus $68.81 per injection for the procedure (CPT 20610) in a doctor's office. Medicare pays 80% and you owe the rest.

Per-unit limits from the CMS October 2026 Medicare Part B payment limit file. Procedure fee is CPT 20610 at 2.06 non-facility RVUs times the CY2026 conversion factor of $33.4009. Course totals assume one knee and the full labeled series. Figures change every quarter.

The Same Company Sells the Same Gel in Two Versions, and the Short One Can Cost More

Three manufacturers sell a five-injection product and a clinically equivalent three-injection product. The pitch for the short version is convenience: fewer trips, fewer needles. For one of the three pairs, that convenience also costs more money, and the extra lands on you as coinsurance.

Hyalgan and Triluron are both sodium hyaluronate from Fidia Pharma, and the three-shot version is allowed at $124.33 more for the course. Look at the drug line alone and the gap is wider: $349.34 of gel for Hyalgan against $611.28 for Triluron, which is 75% more for the equivalent product from the same company.

The other two pairs go the other way, and substantially so. If your clinic offers Supartz FX, Visco-3 is the same gel for $277.35 less. The lesson is not that short courses are bad, it is that the price has no relationship to the number of needles, so you have to ask about the specific brand.

"One Injection Instead of Three" Tells You Nothing About the Price

Single-injection gels are marketed on convenience, and they are genuinely more convenient. But they occupy the full width of the price range, and the two-injection product is the most expensive course Medicare pays for.

Synvisc-One and Monovisc are both a single shot. One is allowed at $357.34 and the other at $694.95, a difference of $337.61 for the same number of visits. Convenience is real; it is just not what sets the price.

What a Year Costs if You Keep Going

Medicare allows a repeat series once at least six months have passed since the last one. That means two courses a year is the maximum, and people with osteoarthritis in both knees get two courses per knee. Here is the same price spread carried out to a full year.

Add the $283 Part B deductible if you have not met it yet. And remember that Original Medicare has no annual out-of-pocket cap, so nothing stops the 20% from recurring year after year. A Medigap policy, a Medicare Advantage plan, or Medicaid is what limits it. See how the Part B no-cap problem works.

Medicare Covers These, but Only After You Fail Everything Cheaper

Gel injections are covered under Part B, not your Part D plan, because a clinician injects them. But coverage is gated, and the gate is where bills go wrong. Across Medicare contractors the criteria are converging on the same list. All of these have to be documented in your chart before the first injection:

• Knee pain that interferes with walking or standing, from osteoarthritis specifically. Any other diagnosis is not covered.
• X-ray evidence of osteoarthritis, such as joint space narrowing or osteophytes. See what a knee X-ray costs.
• At least three months of failed conservative therapy, both non-drug (physical therapy, exercise, weight management, a brace or cane) and drug (acetaminophen, oral or topical NSAIDs, topical capsaicin).
• Failure of, or a contraindication to, a steroid injection first. This is the criterion most people do not know about, and gel injections are explicitly not covered as the initial treatment for knee osteoarthritis.

For a repeat series you also have to have actually improved from the last one, and at least six months must have passed. If the prior series did not help your pain and function, a repeat is not covered.

If a series gets denied partway through, or denied after the fact, you are looking at the full allowed amount rather than 20% of it. That is appealable, and the criteria above are the checklist your appeal has to answer. See how to appeal a denial.

What Medicare's Own Evidence Review Says About Whether These Work

This is worth knowing before you agree to a $999 course, and it comes from the Medicare contractor's own published analysis rather than from us. Reviewing the trial evidence, Noridian concluded that hyaluronic acid injections "did not establish superiority over platelet-rich plasma" for pain and function at intermediate and long-term follow-up, and that hyaluronic acid "yielded similar results when compared with corticosteroids, at intermediate-term follow-up," though the benefit takes longer to arrive with gel.

It also noted that large randomized trials found improvements that were statistically real but did not exceed the threshold for a clinically meaningful difference, and that evidence for protecting cartilage or changing the course of the disease is sparse.

The practical comparison: a steroid injection into the same knee is the same $68.81 procedure fee, and the drug is roughly $5 to $50 instead of $187 to $861. Medicare requires you to try it first anyway. That does not mean gel is worthless, and plenty of people get real relief from it. It does mean a long conversation about the specific brand and the specific price is reasonable, not rude.

Five Things to Check on a Knee Gel Injection Bill

Medicare publishes specific billing rules for these injections, and each one is a place a bill can be wrong in your favor. Pull your statement and your Medicare Summary Notice and check these.

Where You Get It Changes the Bill

The gel costs Medicare the same wherever it is injected. The procedure does not. In a doctor's office the injection is allowed at $68.81. In a hospital outpatient department the physician fee drops to $39.75, but the hospital bills its own facility fee on top, which typically adds a few hundred dollars per visit and is the main reason the same injection costs far more at a hospital clinic.

With a five-injection product, that facility fee lands five times. An independent orthopedic or rheumatology office is almost always the cheaper site for this specific treatment. If ultrasound guidance is used, the procedure code becomes 20611 and the office fee rises to $104.21; Medicare covers guidance when the record explains why it was needed.

How to Pay Less

The Rest of the Knee Osteoarthritis Path

Common Questions

Sources

• CMS, October 2026 Medicare Part B Payment Limit File (ASP pricing files), effective October 1 through December 31, 2026. Per-unit payment limits for J7318 through J7332.
• CMS, CY2026 Physician Fee Schedule Relative Value File, October release. CPT 20610 at 2.06 non-facility and 1.19 facility RVUs; CPT 20611 at 3.12 non-facility. Conversion factor $33.4009.
• CMS Medicare Coverage Database, Proposed LCD DL40456, Hyaluronic Acid Injections for Knee Osteoarthritis (Noridian Healthcare Solutions), posted October 1, 2026, comment period closing November 14, 2026. Coverage criteria, limitations, and summary and analysis of evidence.
• CMS Medicare Coverage Database, LCD L39260 and Billing and Coding Article A59030, Hyaluronic Acid Injections for Knee Osteoarthritis. EJ, JW, JZ, RT, LT and 50 modifier rules; evaluation and management reporting on subsequent injections; one injection service per knee.
• CMS, Medicare Part B Spending by Drug, 2024 release. Utilization and spending by HCPCS code.
• FDA-approved labeling and instructions for use for each product, for the labeled dose and number of injections per series.